参考文献/References:
[1] World Health Organization. Epilepsy[EB/OL]. 2020, http://www.who.int/en/news-room/fact-sheets/detail/epilepsy.
[2] Brodie M, Barry SJ, Bamagous G, et al. Patients of treatment response in newly diagnosed epilepsy[J]. Epilepsia, 2011, 52(6, SI): 10.
[3] Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-Year longitudinal cohort study[J]. JAMA Neurol, 2018, 75(3): 279-286.
[4] Cobos JE. High-dose phenytoin in the treatment of refractory epilepsy[J]. Epilepsia, 1987, 28(2): 111-114.
[5] Yukawa E. Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring[J]. Clin Pharmacokinet, 1996, 31(2): 120-130.
[6] WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system[EB/OL]. 2020, https://www.whocc.no/atc_ddd_index/.
[7] Deckers CP, Genton P, Sills GJ, et al. Current limitations of antiepileptic drug therapy: a conference review[J]. Epilepsy Res, 2003, 53(1/2): 1-17.
[8] Zou XM, Chen JN, An DM, et al. Efficacy of low to moderate doses of oxcarbazepine in adult patients with newly diagnosed partial epilepsy[J]. Seizure, 2015, 29: 81-85.
[9] Horváth L, Fekete K, Márton S, et al. Correlation between prescribed daily dose, seizure freedom and defined daily dose in antiepileptic drug treatment[J]. Int J Clin Pharm, 2017, 39(2): 459-467.
[10] Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy[J]. Epilepsy Behav, 2005, 6(3): 382-387.
[11] Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy[J]. Neurology, 2007, 68(6): 402-408.
[12] Brodie MJ, Barry SJ, Bamagous GA. Effect of dosage failed of first antiepileptic drug on subsequent outcome[J]. Epilepsia, 2013, 54(1): 194-198.
[13] 张杰,高晋健,张德明,等.不同层次水平限定日剂量单药治疗新发癫痫的疗效分析[J].临床神经病学杂志,2018,31(3):161-164.
[14] Hao X, Chen Z, Yan B, et al. Impact of drug manipulation on seizure freedom in adults with uncontrolled epilepsy: a prospective controlled study in rural China[J]. CNS Drugs, 2017, 31(3): 237-243.
[15] Chi X, Li R, Hao XT, et al. Response to treatment schedules after the first antiepileptic drug failed[J]. Epilepsia, 2018, 59(11): 2118-2124.
[16] Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on?[J]. Seizure, 2000, 9(7): 464-468.
[17] Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial[J]. Epilepsy Res, 2003, 57(1): 1-13.
[18] Millul A, Iudice A, Adami M, et al. Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy: An Italian multicenter prospective observational study[J]. Epilepsy & Behavior, 2013, 28(3): 494-500.
[19] Semah F, Thomas P, Coulbaut S, et al. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy[J]. Epileptic Disord, 2014, 16(2): 165-174.
[20] Wang X, He RQ, Zeng QY, et al. Substitution has better efficacy than add-on therapy for patients with focal epilepsy after their first antiepileptic drug treatments fail[J]. Seizure, 2019, 64: 23-28.
[21] Rhee SJ, Shin JW, Lee SH, et al. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy[J]. Epilepsy Res, 2017, 132: 8-14.
[22] Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures[J]. Neurology, 2003, 60(11 Suppl 4): S13-S25.
[23] Schmidt D. Drug treatment of epilepsy: options and limitations[J]. Epilepsy Behav, 2009, 15(1): 56-65.
[24] Bi LE, Park KM, Kim SE, et al. Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy[J]. Epilepsy Res, 2019, 156: 106165.
[25] Abou-Khalil B. Selecting rational drug combinations in epilepsy[J]. CNS Drugs, 2017, 31(10): 835-844.
[26] Brodie M, Covanis T, Gil-Nagel A, et al. Antiepileptic drug therapy: does mechanism of action matter?[J]. Epilepsy Behav, 2011, 21(4): 490; author reply 491.
[27] Verrotti A, Tambucci R, Di Francesco L, et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection[J]. Expert Rev Neurother, 2020, 20(2): 167-173.
[28] Bonnett LJ, Tudur Smith C, Donegan S, et al. Treatment outcome after failure of a first antiepileptic drug[J]. Neurology, 2014, 83(6): 552-560.
[29] Perucca P, Hesdorffer DC, Gilliam FG. Response to first antiepileptic drug trial predicts health outcome in epilepsy[J]. Epilepsia, 2011, 52(12): 2209-2215.
[30] Brodie MJ. Outcomes in newly diagnosed epilepsy in adolescents and adults: Insights across a Generation in Scotland[J]. Seizure, 2017, 44: 206-210.
[31] Camfield PR, Camfield CS, Gordon K, et al. If a first antiepileptic drug fails to control a child’s epilepsy, what are the chances of success with the next drug?[J]. J Pediatr, 1997, 131(6): 821-824.
[32] Bj?ke AB, Nome CG, Falk RS, et al. Evaluation of long-term antiepileptic drug use in patients with temporal lobe epilepsy: Assessment of risk factors for drug resistance and polypharmacy[J]. Seizure, 2018, 61: 63-70.
[33] Kwan P, Brodie MJ. Early identification of refractory epilepsy[J]. N Engl J Med, 2000, 342(5): 314-319.
[34] Zhang Y, Yu N, Su L, et al. A prospective cohort study of prognosis for newly diagnosed epilepsy in East China[J]. BMC Neurol, 2013, 13(1): 116.
[35] Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission[J]. Arch Neurol, 2009, 66(10): 1233-1239.
[36] Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history[J]. Neurology, 2008, 70(1): 54-65.
[37] Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2010, 51(6): 1069-1077.